Patents by Inventor Magnus A. O. Hook

Magnus A. O. Hook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7855272
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: December 21, 2010
    Assignees: Bioresearch Ireland, The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 7834151
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: November 16, 2010
    Assignee: The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 7816494
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: October 19, 2010
    Assignee: The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elizabet Joseffson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Publication number: 20100113349
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: August 24, 2009
    Publication date: May 6, 2010
    Inventors: Joseph M. PATTI, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
  • Patent number: 7709008
    Abstract: Methods for treating or preventing infections from coagulase-negative staphylococci using proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided. Methods are also provided wherein antibodies that recognize the SdrG protein or its ligand binding A region are used to treat or prevent staphylococcal infection, and these methods can also be utilized to prevent the formation of infections on indwelling medical devices.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: May 4, 2010
    Assignees: The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A & M University System
    Inventors: Timothy J. Foster, Kirk McCrea, Magnus A. O. Hook, Stacey Davis, Deirdre Ni Eidhin, Orla Hartford
  • Publication number: 20100081616
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: August 24, 2009
    Publication date: April 1, 2010
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
  • Publication number: 20100008943
    Abstract: An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: August 24, 2009
    Publication date: January 14, 2010
    Inventors: Joseph M. Patti, Timothy J. Foster, Elizabet Joseffson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 7473762
    Abstract: Proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided which are useful in the prevention and treatment of infection caused by coagulase-negative staphylococcal bacteria such as S. epidermidis. The SdrF, SdrG and SdrH proteins are cell-wall associated proteins that specifically bind host proteins and which each have a highly conserved motif of which the consensus sequence is TYTFTDYVD (SEQ ID NO: 16). The proteins and polypetides may be useful in generating antibodies for the diagnosis and treatment of coagulase-negative staphylococcal infections.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: January 6, 2009
    Assignees: The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A&M University System
    Inventors: Timothy J. Foster, Kirk McCrea, Magnus A. O. Hook, Stacy Davis, Deirdre Nieidhin, Orla Hartford
  • Patent number: 7381793
    Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: June 3, 2008
    Assignees: Inhibitex, Inc., BioResearch Ireland, The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 7195763
    Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAVVEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: March 27, 2007
    Assignee: The Texas A & M Univerisity System
    Inventors: Yi Xu, Magnus A. O. Hook
  • Patent number: 6835378
    Abstract: A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal B&bgr; chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogen-binding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: December 28, 2004
    Assignee: The Texas A&M University System University
    Inventors: Stacey Davis, Magnus A. O. Hook
  • Publication number: 20040254354
    Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.
    Type: Application
    Filed: December 24, 2003
    Publication date: December 16, 2004
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
  • Patent number: 6790448
    Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAWEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: September 14, 2004
    Assignee: The Texas A&M University System University
    Inventors: Yi Xu, Magnus A. O. Hook
  • Publication number: 20040141997
    Abstract: Methods for treating or preventing infections from coagulase-negative staphylococci using proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided. Methods are also provided wherein antibodies that recognize the SdrG protein or its ligand binding A region are used to treat or prevent staphylococcal infection, and these methods can also be utilized to prevent the formation of infections on indwelling medical devices.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 22, 2004
    Inventors: Timothy J. Foster, Kirk McCrea, Magnus A.O. Hook, Stacey Davis, Deirdre Ni Eidhin, Orla Hartford
  • Publication number: 20040142348
    Abstract: Proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided which are useful in the prevention and treatment of infection caused by coagulase-negative staphylococcal bacteria such as S. epidermidis. The SdrF, SdrG and SdrH proteins are cell-wall associated proteins that specifically bind host proteins and which each have a highly conserved motif of which the consensus sequence is TYTFTDYVD (SEQ ID NO: 16). The proteins and polypetides may be useful in generating antibodies for the diagnosis and treatment of coagulase-negative staphylococcal infections.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 22, 2004
    Inventors: Timothy J. Foster, Kirk McCrea, Magnus A.O. Hook, Stacey Davis, Deirdre Nieidhin, Orla Hartford
  • Publication number: 20040038327
    Abstract: Antibodies reactive with isolated proteins, designated SdrF, SdrG and SdrH, and their corresponding amino acid and nucleic acid sequences, are provided which are useful in the prevention and treatment of infection caused by coagulase-negative staphylococcal bacteria such as S. epidermidis. The SdrF, SdrG and SdrH proteins are cell-wall associated proteins that specifically bind host proteins and which each have a highly conserved motif of which the consensus sequence is TYTFTDYVD (SEQ ID NO: 16). The antibodies are also useful for the diagnosis and treatment of coagulase-negative staphylococcal infections and may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of coagulase-negative staphylococci to wounds or biomaterials.
    Type: Application
    Filed: July 9, 2003
    Publication date: February 26, 2004
    Inventors: Timothy J. Foster, Kirk McCrea, Magnus A.O. Hook, Stacey Davis, Deirdre Ni Eidhin, Orla Hartford
  • Patent number: 6680195
    Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: January 20, 2004
    Assignees: Inhibitex, Inc., Bioresearch Ireland, The Texas A&M University System
    Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
  • Patent number: 6635473
    Abstract: Isolated proteins, designated SdrF, SdrG and SdrH, and their corresponding amino acid and nucleic acid sequences are provided which are useful in the prevention and treatment of infection caused by coagulase-negative staphylococcal bacteria such as S. epidermidis. The SdrF, SdrG and SdrH proteins are cell-wall associated proteins that specifically bind host proteins and which each have a highly conserved motif of which the consensus sequence is TYTFTDYVD (SEQ ID NO:16). The proteins, antigenic portions thereof and anti-SdrF, SdrG and SdrH antibodies are also useful for the identification and diagnosis of coagulase-negative staphylococcal infections. In particular, the proteins are advantageous because they may be used as vaccine components or antibodies thereof, and they may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of coagulase-negative staphylococci to wounds or biomaterials.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 21, 2003
    Assignees: The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A&M University System
    Inventors: Timothy J. Foster, Kirk McCrea, Magnus A. O. Hook, Stacy Davis, Deirdre Ni Eidhin, Orla Hartford
  • Publication number: 20030044418
    Abstract: A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal B&bgr; chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogen-binding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin.
    Type: Application
    Filed: May 13, 2002
    Publication date: March 6, 2003
    Inventors: Stacey Davis, Magnus A.O. Hook
  • Publication number: 20030021789
    Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAWEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
    Type: Application
    Filed: May 8, 2002
    Publication date: January 30, 2003
    Inventors: Yi Xu, Magnus A.O. Hook